Clinical Trials

Regulatory response to the COVID-19 pandemic: Careful planning to minimize disruptions

Beyond the need to address the ongoing pandemic itself, regulators also must address the impacts to clinical trials as well as essential supplies of treatments and medicines for other diseases and conditions. In this final blog post of our series, we describe strategies to minimize disruption to ongoing clinical trials, drug manufacturing and essential supplies […]

Delays in clinical trials present opportunities for pharma companies to evolve

COVID-19 has upended clinical trial timelines – putting billions of forecasted sales at risk and delaying getting life-saving treatments to patients. This analysis from Garima Kaul, Senior Director, Research and Insights, Decision Resources Group, part of Clarivate, and Jamie Munro, Executive Director, CIRS explores the opportunities that delays in clinical trials present for pharma companies. […]

Biomarkers have several key roles in clinical trials and precision medicine

Biomarker use in clinicals trials has expanded over the last few decades. Designing a protocol that incorporates biomarkers can reduce trial timelines and increase the chance of success. However, biomarkers remain underutilized for a variety of reasons. Evaluating the trends in biomarker use allows us to monitor the effectiveness of new strategies and identify areas […]

What drives the therapy selection test market?

Clarivate medtech expert Sophia Quraishi reviews key factors driving increased demand for premium-priced therapy selection tests.   Therapy selection tests are a form of liquid biopsy, which involve sequencing substrates isolated from bodily fluids, such as blood, saliva or urine. This approach is less invasive, can be used more often and is more cost effective […]

Key ESMO Highlights 2020

As a result of the current COVID-19 pandemic, the annual ESMO Congress was held virtually between 19th and 21st September 2020. Over 2,100 oral presentations and posters were presented, showcasing exciting novel data across oncology, with the ultimate aim of improving cancer patient care. Here DRG/Clarivate highlights the most impactful presentations on drug treatment landscapes. […]

Patient enrollment continues to be a limiting factor for trial durations

To prepare for our recent webinar “Trends in Clinical Trial Planning,” we dug into proprietary data from The Centre for Medicines Research (CMR) International, a wholly owned subsidiary of Clarivate working with leading global pharmaceutical companies to provide insights into industry trends — to strengthen R&D planning and effectiveness.   The length of clinical trials […]

Celebrating 30 years of BioWorld

BioWorld™ has built an enduring relationship with everyone in the drug development and medical technology sectors. As we celebrate our 30th anniversary, we reflect on how the publication has changed over the years to accommodate shifts in media consumption and industry needs.   BioWorld has built an enduring relationship with everyone in the drug development […]

Chasing change: Innovation and patent activity during COVID-19

In just a few short months, COVID-19 swept through the world. To understand the impact of the pandemic on the world’s innovators and measure sentiment, our Derwent™ team asked organizations from a cross-section of industries worldwide about how the pandemic has affected their innovation strategies and the critical role of the IP professional. Read the […]